The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). |
Icahn School of Medicine At Mount Sinai |
| 26431428 |
36 |
Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12). |
Wuxi Apptec |
| 26342867 |
52 |
Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors. |
Sichuan University |
| 25475894 |
68 |
Tetra-substituted pyridinylimidazoles as dual inhibitors of p38a mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases. |
Eberhard Karls Universit£T T£Bingen |
| 25261929 |
20 |
Pyrazole derivatives as potent inhibitors of c-Jun N-terminal kinase: synthesis and SAR studies. |
Kakatiya University |
| 26071372 |
89 |
Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. |
Astellas Pharma |
| 25893042 |
65 |
Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors. |
Translational Research Institute |
| 25835317 |
63 |
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer. |
Sichuan University |
| 25763473 |
108 |
The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents. |
Entremed |
| 25621531 |
114 |
Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors. |
Translational Research Institute |
| 25827523 |
275 |
Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. |
Vertex Pharmaceuticals |
| 25415535 |
118 |
Inhibitors of c-Jun N-terminal kinases: an update. |
Eberhard Karls Universit£T T£Bingen |
| 25341110 |
66 |
Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. |
Genentech |
| 24938496 |
32 |
Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept. |
Aska Pharmaceutical |
| 25589933 |
38 |
Unfolded Protein Response in Cancer: IRE1a Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability. |
Amgen |
| 25393557 |
83 |
Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives. |
Translational Research Institute |
| 24650640 |
43 |
Discovery of 4-anilinoa-carbolines as novel Brk inhibitors. |
Martin-Luther-University Halle-Wittenberg |
| 23498914 |
32 |
Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects. |
Hanyang University |
| 23570561 |
80 |
Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors. |
The Scripps Research Institute |
| 23416008 |
29 |
3D-QSAR studies of 1,2-diaryl-1H-benzimidazole derivatives as JNK3 inhibitors with protective effects in neuronal cells. |
Hanyang University |
| 23416002 |
126 |
Amino acid derived quinazolines as Rock/PKA inhibitors. |
Translational Research Institute |
| 23394126 |
170 |
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). |
Exelixis |
| 19303774 |
87 |
1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3. |
Glaxosmithkline |
| 17194588 |
92 |
N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. |
Glaxosmithkline |
| 22621397 |
39 |
Irreversible protein kinase inhibitors: balancing the benefits and risks. |
Covalution Pharma |
| 22858099 |
52 |
Discovery of potent and selective rhodanine type IKKß inhibitors by hit-to-lead strategy. |
Korea University |
| 22738630 |
76 |
Structure-based optimization of aminopyridines as PKC¿ inhibitors. |
Vertex Pharmaceuticals |
| 24900264 |
106 |
The Discovery of VX-745: A Novel and Selective p38a Kinase Inhibitor. |
TBA |
| 21353571 |
26 |
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. |
Hanyang University |
| 20138514 |
93 |
3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta. |
Vertex Pharmaceuticals |
| 19947601 |
24 |
Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. |
Translational Research Institute |
| 18183025 |
12060 |
A quantitative analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
| 19394223 |
50 |
Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. |
Glaxosmithkline |
| 18789685 |
172 |
Kinase array design, back to front: biaryl amides. |
Glaxosmithkline |
| 16038553 |
2 |
Latifolians A and B, novel JNK3 kinase inhibitors from the Papua New Guinean plant Gnetum latifolium. |
Griffith University |
| 18313930 |
30 |
Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (2). |
Takeda Pharmaceutical |
| 18077363 |
314 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
University of Oxford |
| 17983756 |
55 |
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. |
Osi Pharmaceuticals |
| 18278858 |
93 |
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. |
Amgen |
| 18313304 |
50 |
Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1). |
Takeda Pharmaceutical |
| 16876403 |
85 |
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. |
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories |
| 15999997 |
85 |
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. |
Serono Pharmaceutical Research Institute |
| 15214773 |
76 |
Fragment-based drug discovery. |
Sunesis Pharmaceuticals |
| 17018693 |
30 |
Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. |
Glaxosmithkline |
| 16249345 |
25 |
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. |
Glaxosmithkline |
| 22244937 |
44 |
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. |
Celgene |
| 22226655 |
88 |
Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury. |
Celgene |
| 22014550 |
337 |
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). |
Ansaris |
| 22004719 |
56 |
Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors. |
The Scripps Research Institute |
| 21999461 |
90 |
1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase. |
RhôNe-Poulenc Rorer |
| 22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
| 21936542 |
143 |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. |
Novartis Institute For Biomedical Research |
| 21813278 |
95 |
Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration. |
Elan Pharmaceuticals |
| 21620699 |
51 |
Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors. |
Pfizer |
| 21570836 |
78 |
Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement. |
Elan Pharmaceuticals |
| 21515047 |
24 |
3-Amino-pyrazolo[3,4-d]pyrimidines as p38a kinase inhibitors: design and development to a highly selective lead. |
Roche Palo Alto |
| 21489792 |
26 |
Discovery of piperidinyl aminopyrimidine derivatives as IKK-2 inhibitors. |
Korea Institute of Science and Technology |
| 21185177 |
30 |
Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors. |
The Scripps Research Institute |
| 21375264 |
77 |
Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors |
Roche Palo Alto |
| 21316221 |
62 |
Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors. |
The Scripps Research Institute |
| 21316234 |
133 |
Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor. |
Elan Pharmaceuticals |
| 21112785 |
151 |
Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. |
Elan Pharmaceuticals |
| 21071223 |
190 |
Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. |
Elan Pharmaceuticals |
| 19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). |
Ambit Biosciences |
| 20675134 |
88 |
Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship. |
Daiichi Sankyo |
| 20655210 |
3 |
X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors. |
Roche Palo Alto |
| 20684608 |
73 |
Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. |
The Scripps Research Institute |
| 20146479 |
31 |
Small molecule JNK (c-Jun N-terminal kinase) inhibitors. |
Merck Research Laboratories |
| 19950901 |
23 |
Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. |
Roche Palo Alto |
| 20166671 |
85 |
Selectively nonselective kinase inhibition: striking the right balance. |
Schering-Plough |
| 19837589 |
52 |
Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors. |
Translational Research Institute and Department of Molecular Therapeutics |
| 20078117 |
27 |
Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors. |
Eberhard-Karls-University of T£Bingen |
| 19591487 |
38 |
3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta. |
Eberhard-Karls University |
| 19361991 |
80 |
Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors. |
Vertex Pharmaceuticals |
| 19574047 |
42 |
Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase. |
Amgen |
| 19414255 |
58 |
Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase. |
Vertex Pharmaceuticals |
| 19327989 |
40 |
Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. |
Pfizer |
| 19035792 |
85 |
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
Glaxosmithkline |
| 18996009 |
36 |
Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. |
The Scripps Research Institute-Florida |
| 18990570 |
72 |
Chroman-3-amides as potent Rho kinase inhibitors. |
The Scripps Research Institute |
| 18817365 |
73 |
Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold. |
Amgen |
| 18602262 |
56 |
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. |
Glaxosmithkline |
| 18482836 |
14 |
IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding. |
Ucb Pharma |
| 18207396 |
10 |
Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors. |
Eberhard-Karls University |
| 17911023 |
26 |
3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors. |
Scripps Florida |
| 17459703 |
111 |
Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. |
Ucb Pharma |
| 17451961 |
19 |
Assessing potency of c-Jun N-terminal kinase 3 (JNK3) inhibitors using 2D molecular descriptors and binary QSAR methodology. |
Aureus Pharma |
| 17350837 |
59 |
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors. |
Amgen |
| 17323937 |
12 |
From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors. |
Eberhard-Karls-University TüBingen |
| 17289388 |
8 |
Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. |
Tibotec |
| 17055723 |
17 |
Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: implication for targeting protein kinases in metabolic diseases. |
Abbott Laboratories |
| 16970394 |
147 |
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. |
Amgen |
| 16516473 |
444 |
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. |
Astrazeneca |
| 16337120 |
53 |
Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3. |
Astrazeneca R&D SöDertäLje |
| 16153829 |
14 |
The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold. |
University College London |
| 16140012 |
30 |
Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. |
Astrazeneca R&D SöDertäLje |
| 15711537 |
653 |
A small molecule-kinase interaction map for clinical kinase inhibitors. |
Ambit Biosciences |
| 15615541 |
2 |
Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase. |
Serono Pharmaceutical Research Institute |
| 15317461 |
53 |
Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. |
Glaxosmithkline |
| 12672234 |
64 |
Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase. |
Boehringer Ingelheim Pharmaceuticals |
| 12482439 |
51 |
Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. |
Merck Research Laboratories |
| 21381887 |
3 |
Synthesis and biological evaluation of fused oxepinocoumarins as free radicals scavengers. |
Aristotle University of Thessaloniki |
| 28340404 |
12 |
Synthesis, in vitro antiproliferative activity and kinase profile of new benzimidazole and benzotriazole derivatives. |
Warsaw University of Technology |
| 2877462 |
17 |
1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. |
The Oregon Health Sciences University |
Search and Browse
